drugset / Trial / NCT07301008

Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US

NCT07301008

Phase 4 Recruiting 60 enrolled Medstar Health Research Institute Pfizer · collab
NaSingle-groupOpen-labelPrevention

Summary

Single-center, open label, prospective study conducted at Medstar Georgetown Headache Center. Men and woman ≥ 18 years old that are diagnosed with migraine with or without aura for at least 1 year, who report a reliable migraine trigger. Acceptable triggers for the study will include exercise, alcohol (less than one drink per day for woman and less than two drinks per day for men), air travel that lasts no more than 12 hours, sexual activity, fasting that lasts no more than 24 hours, stress or stress let-down headache.

Timeline

Start
2025-09-09
Primary completion
2026-09
Completion
2027-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Rimegepant Small molecule 75 mg

Indications